

PRODUCT INFORMATION

Common Name	MM-121,MM121,SAR256212
Conjugate	Unconjugated
Synonyms	HER3, ERBB3
Applications	ELISA, Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens
IgG type	Human IgG2(S378A) - Kappa
Reactivity	Human
Target	HER3
Uniprot ID	P21860
Description	Anti-Her3(seribantumab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only

DIMA BIOTECH CONFIDENTIAL



Anti-Her3(seribantumab biosimilar) mAb ELISA

0.2 μg of Human Her3, His tagged protein per well




Figure 1. ELISA plate pre-coated by 2 $\mu\text{g}/\text{mL}$ (100 $\mu\text{L}/\text{well}$) Human Her3 Protein, His Tag (PME100088) can bind Anti-Her3(seribantumab biosimilar) mAb (BME100244) in a linear range of 0.13-16 ng/mL.




Figure 2. Flow cytometry analysis with 1 $\mu\text{g}/\text{mL}$ Anti-Her3(seribantumab biosimilar) mAb (BME100244) on HEK293 cells transfected with Human Her3 protein (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).






Figure 3. Flow cytometry analysis of antigen binding of anti-human Her3 mAb(BME100244).

(A) BME100244 does not bind to 293T cells that do not express Her3.

(B) A clear peak shift of BME100244 was seen compared to the control when incubated with Her3-expressing HT55 cells, indicating strong binding of BME100244 to Her3. Antibodies were incubated at 5 µg/mL.

DIMABIO CONFIDENTIAL

